-
Product Insights
New![]()
Net Present Value Model: Capricor Therapeutics Inc’s CAP-1002
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TLC-6740 in Lipodystrophy (Lipoatrophy)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TLC-6740 in Lipodystrophy (Lipoatrophy) Drug Details: TLC-6740 is under development for the treatment of lipodystrophy,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rademikibart in Eosinophilic Esophagitis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rademikibart in Eosinophilic Esophagitis Drug Details: CBP-201 is under development for the treatment of allergic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tozorakimab in Asthma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tozorakimab in Asthma Drug Details: Tozorakimab (MEDI-3506) is under development for the treatment of diabetic kidney disease,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAP-1002 in Pulmonary Arterial Hypertension
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CAP-1002 in Pulmonary Arterial Hypertension Drug Details:CAP-1002 is under development for the treatment of pulmonary arterial...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAP-1002 in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CAP-1002 in Congestive Heart Failure (Heart Failure) Drug Details:CAP-1002 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CAP-1002 in Duchenne Muscular Dystrophy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CAP-1002 in Duchenne Muscular Dystrophy Drug Details:CAP-1002 is under development for the treatment of pulmonary arterial...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Itacitinib Adipate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Itacitinib Adipate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details: Itacitinib adipate (INCB-39110) is under...
-
Product Insights
![]()
Net Present Value Model: CAP-1002
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CAP-1002 Drug Details CAP-1002 is under...
-
Product Insights
![]()
Hypertension Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. The Hypertension pipeline market research report provides comprehensive information on the therapeutics under development for Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.